Psychiatry · Antipsychotic
The FDA's approval of a generic version of Lurasidone Hydrochloride by InvaGen Pharmaceuticals signifies increased competition in the antipsychotic market. This could lead to pricing pressures and shifts in market share that require strategic reassessment by existing players.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/19/2026, 12:32:22 AM
Assessment confidence: 75% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of a generic version of Lurasidone Hydrochloride by InvaGen Pharmaceuticals signifies increased competition in the antipsychotic market. This could lead to pricing pressures and shifts in market share that require strategic reassessment by existing players. Regulatory context from FDA (FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (11 high-relevance).
Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for existing Lurasidone products. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Psychiatry · Antipsychotic, 7 regulatory and 1 competitive items passed relevance filtering for InvaGen Pharmaceuticals.
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). This approval allows InvaGen to enter the market with a generic antipsychotic, potentially impacting the sales of branded competitors.
Regulatory risk is concentrated around FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda). While the approval itself is a standard regulatory process, the implications for compliance and market dynamics will need ongoing monitoring as the generic product enters the market.
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — RILPIVIRINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — SOTALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceLong-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTrends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of a generic version of Lurasidone Hydrochloride by InvaGen Pharmaceuticals signifies increased competition in the antipsychotic market. This could lead to pricing pressures and shifts in market share that require strategic reassessment by existing players.
The entry of a generic competitor is likely to significantly affect revenue and market share for branded Lurasidone products, necessitating adjustments in pricing and marketing strategies.
While the approval itself is a standard regulatory process, the implications for compliance and market dynamics will need ongoing monitoring as the generic product enters the market.
Monitor market entry timelines and pricing strategies from InvaGen and competitors.
Track for follow-up milestones; no immediate action required.